BACKGROUND: In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance. DISCUSSION: One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma. CONCLUSION: Considering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.
BACKGROUND: In the Dukes' B and C stages of colorectal carcinoma there are considerable variations in the observed courses of the disease. Since post-operative chemotherapy in patients with Dukes' C (node-positive) colon carcinoma has been demonstrated to be effective in improving overall-survival, a more exact prognosis assessment gains additional significance and therapeutic relevance. DISCUSSION: One also hopes to derive improved prognostic factors from the clarification of the molecular pathogenesis. Because of its frequency and the accessibility and recognizability of its developmental stages colorectal carcinoma is among the best investigated of all solid tumors. Despite a multitude of suggested molecular candidate markers none of these changes has yet been able enter the everyday life of the clinic. However, it is to be expected that some of the molecular alterations presently discussed will gain importance before long in the clinical treatment of patients with colorectal carcinoma. CONCLUSION: Considering also our own findings, this review presents the latest developments in the scientific discussion of the tumor suppressor/oncogenes p53, k-ras, and DCC, biochemical determinants of the 5-fluorouracil metabolism, and defects of the DNA repair system.
Authors: W S Samowitz; K Curtin; D Schaffer; M Robertson; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-11 Impact factor: 4.254
Authors: M Kornmann; K H Link; H J Lenz; J Pillasch; R Metzger; U Butzer; G H Leder; M Weindel; F Safi; K D Danenberg; H G Beger; P V Danenberg Journal: Cancer Lett Date: 1997-09-16 Impact factor: 8.679
Authors: H Bouzourene; P Gervaz; J P Cerottini; J Benhattar; P Chaubert; E Saraga; S Pampallona; F T Bosman; J C Givel Journal: Eur J Cancer Date: 2000-05 Impact factor: 9.162
Authors: V J Bubb; L J Curtis; C Cunningham; M G Dunlop; A D Carothers; R G Morris; S White; C C Bird; A H Wyllie Journal: Oncogene Date: 1996-06-20 Impact factor: 9.867
Authors: J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton Journal: N Engl J Med Date: 1994-07-28 Impact factor: 91.245
Authors: Muriel X G Draht; Kim M Smits; Benjamin Tournier; Valerie Jooste; Caroline Chapusot; Beatriz Carvalho; Arjen H G Cleven; Sarah Derks; Kim A D Wouters; Eric J T Belt; Hein B A C Stockmann; Herman Bril; Matty P Weijenberg; Piet A van den Brandt; Adriaan P de Bruïne; James G Herman; Gerrit A Meijer; Françoise Piard; Veerle Melotte; Manon van Engeland Journal: Mol Oncol Date: 2014-02-02 Impact factor: 6.603
Authors: David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber Journal: Mod Pathol Date: 2019-08-30 Impact factor: 7.842
Authors: Maria S Pino; Hirotoshi Kikuchi; Min Zeng; Maria-Teresa Herraiz; Isabella Sperduti; David Berger; Do-Youn Park; A John Iafrate; Lawrence R Zukerberg; Daniel C Chung Journal: Gastroenterology Date: 2009-12-21 Impact factor: 22.682
Authors: Kim M Smits; Trupti Paranjape; Sunitha Nallur; Kim A D Wouters; Matty P Weijenberg; Leo J Schouten; Piet A van den Brandt; Fred T Bosman; Joanne B Weidhaas; Manon van Engeland Journal: Clin Cancer Res Date: 2011-10-12 Impact factor: 12.531
Authors: V Deschoolmeester; C Boeckx; M Baay; J Weyler; W Wuyts; E Van Marck; M Peeters; F Lardon; J B Vermorken Journal: Br J Cancer Date: 2010-10-19 Impact factor: 7.640
Authors: Shuji Ogino; Jeffrey A Meyerhardt; Natsumi Irahara; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs Journal: Clin Cancer Res Date: 2009-11-24 Impact factor: 12.531
Authors: Garrett M Nash; Mark Gimbel; Alfred M Cohen; Zhao-Shi Zeng; Mackevin I Ndubuisi; Daniel R Nathanson; Jurg Ott; Francis Barany; Philip B Paty Journal: Ann Surg Oncol Date: 2009-10-08 Impact factor: 5.344